

Vitrolife - A robust first quarter in 2023

Vitrolife enters 2023 with good progress and 9% organic growth. All three lines of business contribute. It is also reassuring that Genetic Services delivers a quarter with 7% organic growth. The gross margin is an important value driver, and the 56.7% gross margin is a distinctive improvement. Our updated view is a base case valuation of SEK 295 (285) and a Bull Case of SEK 425 (400), and a Bear Case of SEK 140 (140).

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

Vitrolife - A robust first quarter in 2023